GlassScriptPhysician profile
Forrest C Jellison
NPI 1508073511
$4,977.40
in general payments reported to CMS, 2019-2025
15 companies · $421 in 2025
The $421 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,744 · 2020: $88.81 · 2021: $354 · 2022: $597 · 2023: $1,594 · 2024: $178 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292 · Travel and Lodging: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,292.09 |
| Travel and Lodging | $901.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,400.78 | 2021-2025 | Interstim |
| Medtronic USA, INC. | $1,325.95 | 2019 | |
| Boston Scientific Corporation | $1,200.79 | 2023-2025 | Ams 700, Advance Xp |
| Coloplast Corp | $365.16 | 2019-2025 | |
| Allergan, INC. | $174.81 | 2019-2022 | |
| Valencia Technologies Corporation | $92.50 | 2022 | |
| Abbvie INC. | $82.20 | 2022-2025 | |
| Astellas Pharma US INC | $78.43 | 2019 | |
| Urogen Pharma, INC. | $72.83 | 2025 | |
| Dendreon Pharmaceuticals LLC | $56.73 | 2025 | Provenge |
| Axonics, INC. | $34.83 | 2021 | |
| Sumitomo Pharma America, INC. | $28.63 | 2025 | Gemtesa |
| Ambu INC. | $22.12 | 2021 | |
| Novo Nordisk INC | $21.03 | 2024 | |
| Pelvital USA, INC. | $20.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Forrest Jellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.